First results of abciximab (ReoPro) in the treatment of acute myocardial infarction and primary PTCA: the GRAPE pilot study by Merkhof, L.F.M. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25863
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
1-474 Supplement 1
LD+H LD-H HD+H HD-H H
Death
(n=372)
12.6%
(n=364)
14.7%
(n=3S7)
18.0%
(n=387)
14.7%
(n=731)
18%
or Ml
0.66
(0.46,0.94)
0.78
(0.55,1.11)
1.00
(0.72,1.39)
0.78
(0.56,1.10)
•
Odds ratios on the death/MI composite of LD and HD vs control were 0.72(0.54,0,95) and 
0.89(0.68,1.16), respectively. Lamifiban with and without H exerted a consistent effect in 
reducing clinical events at 6 months, The combination of LD+H had the best profile compared 
with standard therapy.
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Pronounced Reduction in Long-Term Ischemic Events With Platelet llb/llla 
Antagonism Among Diabetics With Unstable Angina: PARAGON 6-Month 
Results
David J Moliterno, Cleveland Clinic Foundation, Cleveland, OH; Robert A Harrington, Duke 
University, Durham, NC; Kristin Newby, Duke University Medical Center, Durham, NC; Manju 
Bhapkar, Duke Clinical Research Institute, Durham, NC; Hakan Emanuelsson, Irebro Medical 
Center!, Irebro Sweden; Paul W Armstrong, University of Alberta, Edmonton, AB Canada; Eric J 
Topol, Cleveland Clinic Foundation, Cleveland, OH
Diabetic patients have heightened platelet aggregability and worse outcomes after acute 
coronary syndromes compared with non-diabetics. To discern the possible benefit of potent 
platelet llb/llla antagonism (lamifiban) among diabetic patients with unstable angina, we 
prospectively collected data from the PARAGON trial. PARAGON, a randomized, double-blind, 
placebo-controlled, 2282-patient trial of lamifiban in unstable angina, included 412 patients with 
diabetes. All patients received aspirin and either IV lamifiban (1ji g/min or 5\i g/mln) or placebo 
for 72 hours. Compared with non-diabetics, diabetics were older and had more risks for CAD, 
Lamifiban-treated diabetics had a 29% lower incidence of death or myocardial infarction than 
placebo at 30 days (11,0% vs, 15.4%). At 6 months, diabetic patients treated with placebo had 
the highest rate of death, myocardial infarction, or the composite (Table). This adverse 
composite event rate was reduced by 36% with lamifiban (26.2% vs. 16,7% , *p<0.01). Non- 
diabetics had lower event rates than diabetics, and experienced only minimal reduction in events 
with lamifiban. In contrast, diabetic patients with acute coronary syndromes derive a particularly 
pronounced long-term benefit with early platelet llb/llla blockade,
6-Month Adverse Events
Diabetes No Diabetes
Placebo Lamifiban Placebo Lamifiban
Death, % 14.6 9.2* 4.9 5.1
Ml, % 18.5 10.6* 12.7 11.8
Death/Ml, % 26.2 16.7* 15.4 14,1
Enhanced Anti-Platelet Therapy is More Important Than Choice of 
Thrombolytic Agent in the Treatment of Myocardial Infarction
2647
Mitchell W Krucoff, Cynthia L Green, Kathleen M Trollinger, Arthur Maas, Duke University 
Medical Center, Durham, NC; David J Moliterno, Cleveland Clinic Foundation, Cleveland, OH; 
Robert A Harrington, Duke University, Durham, NC; Christopher M O'Connor, Duke University 
Medical Center, Durham, NC; James E Pope, Tampa Cardiovascular Associates, Tampa, FL
Mortality in ST-elevation Ml is lower in patients treated with thrombolytic therapy than in those 
who are not. A small but further reduction in mortality has been reported based on the lytic agent 
selected, To assess the incremental benefit of adjunctive anti-platelet therapy to that of the lytic 
agent selected, ST-segment recovery analysis parameters known to reflect speed and stabilityof 
patency and clinical outcome were reviewed from all 1,108 analyzable continuous 12-lead ST- 
segment recordings available from the PARDIGM (253), PRIME (189), IMPACT-AMl-l (122), 
DUCCS-II (38), TAMI-9 (253) and GUSTO-i (253) trials, All pts had <6 hr pain and ST elevation 
on initial ECG. There were 907 pts treated with tPA and 201 with SK/APSAC (SK); 254 were 
treated with either lamifiban or integrilin parenteral (PLT) and 854 received no PLT; all pts had 
ASA. ST-segment recovery endpoints analyzed blinded to treatment or outcome included: PEAK 
ST deviation during the monitoring period (uV); time from onset of lytics to STABLE ST recovery 
of >50% (min); % of pts with early ST recovery & re-eievatlon suggesting CYCLIC flow of the 
infarct artery; LATE ST re-elevation after >4 hrs of STABLE ST recovery; and re-elevation 
episodes (RE*ST), and ST AREA (uV-min) under the level vs. time trend curve. Results, as % or 
50» (25th, 75ai %lle) were:
Thus: 1) enhanced anti-PLT activity has a more profound influence on the physiology of acute Ml 
than the choice of lytic agent, and 2) this influence appears to be more in the speed with which 
stable reperfusion occurs than in the elimination of late events.
Variable PEAK ST STABLE CYCLIC LATE REST AREA
PLT* 395 89 17% 11% 29% 4643
(230,665) (33,155) (0,9694)
No PLT4 482 128 32% 16% 47% 6050
(300,705) (58,241) (1287,12
603)
SK+ 475 126 31% 20% 47% 7165
(305,710) (59,206) , (2012,13
, , 850)
tPA+ 455 112 28% 14% 42% 4838
(269,700) (41,215) • (531,112
26)
*p-value .002 <.001 <001 .094 <.001 . .005
+p-value .166 .588 .363 .045 .219 .010
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Early coronary patency evaluation of a platelet glycoprotein receptor 
antagonist (abciximab) in primary PTCA: the GRAPE-plIot study
Lambert F M Merkhof-Van Den, University Hospital, Nijmegen Netherlands; Aylee Liem, Felix 
Zijlstra, Weezenlanden Hospital Zwolle, Zwoile Netherlands; Hans Olsson, Örebro Medical 
Center Hospital, Örebro Sweden; Helena Nilsson, Lars Grip, Sahigrenska University Hospital, 
Gothenburg Sweden; Gerrit Veen, Free University Hospital, Amsterdam Netherlands; Chris <Je 
Zwaan, Frits Whm Bar, Coen van der Zwaan, University Hospital Rotterdam Netherlands; 
Maarten L Simoons, Erasmus University, Rotterdam Netherlands; Freek W,A. Verheugt,
University Hospital, Nijmegen Netherlands
The best treatment of acute myocardial infarction (AMI) is achieving early patency of the infarct 
related artery (IRA), The results of thrombolysis and primary PTCA are already known, There is 
hardly any information about the effect of platelet glycoprotein receptor antagonist on eartj 
patency in AMI. In the GRAPE (Glycoprotein Receptor Antagonist Patency Evaluation) pi tot trial 
we studied 41 patients (pts) with < 6 hour AMI eligible for primary PTCA and with a total of 10 
mm ST-segment elevation or more. At hospital admission all pts were given oral aspirin 160 mj 
and 5,000 U iv heparin together with a bolus of abciximab (ReoPro®) 0.26 mg/kg follow©! by i 
12 hour infusion of 10 mcg/min. As soon as possible the pts were brought to ttie catheterisaSkw 
lab to undergo angiography and, if necessary, primary PTCA, Results: Median time between 
abciximab bolus and first injection for angiography was 45 minutes (range 10-90), The culprit 
lesion was found to be the RCA in 17 pts, the RCX in 3 and the LAD in 21 pts. At first 1RA 
injection there was a TIMI flow grade 3 in 12 (30%) pts. Two pts (5%) showed TIMl flow grade I  
3n 27 (65%) pts the IRA was totally occluded (TIMl flow grade 0 and 1). Conclusion: These 
preliminary data suggest, that abciximab given early in patients with a large AMI eligible for 
primary PTCA can achieve IRA patency in a third of the pts.
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A Randomized, Placebo-Controlled Crossover Trial of ReoPro Alone or 
Combined with Low-Dose Plasminogen Activator for Coronary Reperfusion in 
Patients with Acute Myocardial Infarction: Preliminary Results
Herman K Gold, Massachusetts General Hospital, Boston, MA; Dean J Kereiakes, Lindner 
Cardiovascular Research, Cincinnati, OH; Robert E Dinsmore, Massachusetts General Hospilai, 
Boston, MA; Linda H Martin, David Lausten, Lindner Cardiovascular Research, Cincinnati, OH; 
Thomas M Broderick, Ohio Heart Health Center, Cincinnati, OH; Keaven M Anderson, Centccor, 
Malvern, PA; Harry D Garabedian, Robert C Leinbach, Massachusetts General Hospital, Boston, 
MA
We have previously observed rapid initiation of coronary flow by ReoPro without exogenous 
plasminogen activators (EPA) in patients (pts) with acute coronary occlusion. In an ongoing 
double-blind, placebo-controlled, crossover trial of ReoPro alone or in conjunction with low-dose 
Actlvase, 26 pts within 6 hr of onset of acute myocardial infarction (AMI) and ST segmenl 
elevation have received aspirin (325 mg PO) and heparin (70 Unit/kg bolus pius 7 Unit/kg^ 
continuous infusion IV), followed by randomization to blinded ReoPro (0.25 mgftg IV bolus) or 
placebo. The primary objective is to document infarct-related artery (IRA) patency within 60-90 
min after ReoPro alone; the effect of adjunctive Activase on IRA patency is the secondary go& 
Protocol: Angiography of the IRA is performed at 60-90 min (Angio # 1) after initial therapy, art 
pts then cross over to blinded ReoPro or placebo bolus, whichever was not initially given. Angio
# 2 is performed 10 min later. Pts not achieving TIMl 3 flow are further randomized to b-linfed 
Activase (20 mg IV) or placebo bolus, and Angio # 3 performed 15 min later. Blinded results to 
date: Treatment was initiated 2.9± 1 (mean± SD) hr after onset, and Angio # 1 performed
14 min after randomization. At the time when all pts have had ReoPro alone for 10-90 min {Angio
# 2), IRA flow was TIMl 0 in 8 pts, TIMl 1 in 5 pts, TIMl 2 in 5 pts, and TIMl 3 in 8 pts. An 
additional 22 pts will be enrolled. Conclusions: In this first randomized trial of a selective 
platelet glycoprotein llb/llla receptor antagonist for reperfusion, alone or with low-dose adjunctive 
EPA, preliminary angiographic data shows that 50% of pts had TIMl 2 or 3 flow after ReoPro 
treatment alone.
2650
Angiographic Results from Platelet Receptor Inhibition for Ischemic Syndrome 
Management in Patients with Documented Unstable Angina or Non-Q-wave Ml 
(PRISM'Plus)
Xue-Qiao Zhao, University of Washington, Seattle, WA; Steven Snapinn, Frederic L Sax, Merc)« 
Research Laboratories, West Point, PA; Edward L Bolson, Joseph W Davis, University of 
Washington, Seattle, WA; C Joy Lis, Asma F Ghannam, Lawrence I Deckelbaum, Merck 
Research Laboratories, West Point, PA; Pierre Theroux, Montreal Heart Institute, Montreal 
Canada
The angiographic (angio) study in PRISM-Plus was designed to examine the effect of tiro fib an 
(Tir), a non-peplide platelet GP llb/llla receptor blocker, compared to heparin (Hep) on angio- 
detected irtracoronary thrombus (THR). 1168 pts with documented unstable angina or non-Q~ 
wave Mi were randomized to Hep or to CTH and had angiography a mean of 65± 17 hrs (0-97) 
after the randomization. Culprit lesions were identified based on the ECG ischemic region and 
the details of coronary anatomy and analyzed by the Core Lab, blinded to treatment, THR was 
analyzed using the TIMl-THR grade: Q=absent, Impossible, 2=small {<0.5 x normal lumen 
diameter (NLD) at the greatest dimension), 3= medium (0.5-1.5 x NLD), 4=large (>1.5 x NLD), 
5=recent total occlusion. Flow past the culprit lesion was assessed using TIM I-flow grade. The 
primary and secondary angio endpoints were the % of pts with each grade of TH R and TIMl flow 
past the culprit lesion. Results: For 580 pts in CTH, the % of pts in THR grade 0-5 were 58,12, 
12,12, 2 and 4, but were 53,12,9,17, 3 and 6 for 588 pts in Hep (p=0.D2). The % of pts with 
TIMI-flow grade 3-0 were 82, 9, 1 and 8 in CTH, versus 74, 13, 2 and 11 in Hep (p=0.002)- 
Conclusions: In PRJSM-Plus, compared to Hep alone, the CTH significantly reduced the
